PE anti-mouse CD80 Antibody

Pricing & Availability
Clone
16-10A1 (See other available formats)
Regulatory Status
RUO
Other Names
B7-1, B7, Ly-53
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
16-10A1_PE_032309.jpg
Thioglycolate-elicited Balb/c mouse peritoneal macrophages stained with 16-10A1 PE
  • 16-10A1_PE_032309.jpg
    Thioglycolate-elicited Balb/c mouse peritoneal macrophages stained with 16-10A1 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
104707 50 µg 88€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104708 200 µg 235€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD80 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD80 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD80 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD80 appears to be expressed later in the immune response than CD86. CD80 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Reported Reactivity
Dog
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
CHO cell line transfected with mouse B7 (CD80)
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation2, in vitro and in vivo blocking of CTLA-4 Ig to CD80 by blocking costimulation of T cells by activated B cells2-4, and immunohistochemical staining of acetone-fixed frozen sections1,4. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104747-104752).

Application References

(PubMed link indicates BioLegend citation)
  1. Harlan DM, et al. 1994. P. Natl. Acad. Sci. USA 91:3137. (IHC)
  2. Razi-Wolf Z, et al. 1992. P. Natl. Acad. Sci. USA 89:4210. (Block, IP)
  3. Hathcock KS, et al. 1994. J. Exp. Med. 180:631. (Block)
  4. Herold KC, et al. 1997. J. Immunol. 158:984. (Block, IHC)
  5. Ma XT, et al. 2006. Cancer Res. 66:1169.
  6. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC)
  7. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  8. Turnquist HR, et al. 2007. J. Immunol. 178:7018.
  9. Misra RS, et al. 2010. J. Exp Med. 207:1775. PubMed
  10. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  11. Philipsen L, et al. 2013. Mol Cell Proteomics. 12:2551. PubMed
Product Citations
  1. Koyama M, et al. 2015. J Exp Med. 212: 1303 - 1321. PubMed
  2. Rozanski C, et al. 2011. J Exp Med. 208:1435. PubMed
  3. Mulder R, et al. 2017. Front Immunol. 1.464583333. PubMed
  4. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  5. Wilhelm J, et al. 2021. J Control Release. 329:353. PubMed
  6. Takeda Y, et al. 2018. Innate Immun. 24:323. PubMed
  7. Kashyap AS, et al. 2019. Cell Rep. 28:3367. PubMed
  8. Wei H, et al. 2021. Malar J. 20:89. PubMed
  9. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  10. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  11. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  12. Waide ML, et al. 2020. Cell Rep. 33:108503. PubMed
  13. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  14. Nagaoka M, et al. 2014. J Immunol. 193:2812. PubMed
  15. Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed
  16. Rafiq S, et al. 2018. Nat Biotechnol. 36:847. PubMed
  17. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  18. Mardomi A, et al. 2021. J Cell Physiol. 236:6328. PubMed
  19. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  20. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  21. Bhattacharjee P, et al. 2018. Sci Rep. 13:e0199785. PubMed
  22. Wu J, et al. 2021. Mol Med Rep. 23:. PubMed
  23. Wong R, et al. 2020. Immunity. 53(5):1078-1094.e7. PubMed
  24. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  25. Lin SY, et al. 2017. Autophagy. 14:778. PubMed
  26. Utley A, et al. 2020. Cell Rep. 31:107815. PubMed
  27. Tsukasaki M, et al. 2020. Cell Reports. 32(10):108124. PubMed
  28. Zhang L, et al. 2021. J Immunother Cancer. 9:. PubMed
  29. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  30. Zhang F, et al. 2017. Mol Immunol. 10.1016/j.molimm.2017.06.019. PubMed
  31. Pardy RD, et al. 2021. Nat Commun. 12:4051. PubMed
  32. Coe D, et al. 2022. JCI Insight. 7:. PubMed
  33. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  34. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  35. Xie Z, et al. 2018. J Am Heart Assoc. 7:e007442. PubMed
  36. Florêncio KGD, et al. 2022. Front Immunol. 13:941757. PubMed
  37. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  38. Guo L, et al. 2021. Vaccines (Basel). 9:. PubMed
  39. Ganesan R, et al. 2020. FASEB J. 34:15888. PubMed
  40. Pilones KA, et al. 2020. Cancer Immunol Res. 8:1054. PubMed
  41. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  42. Wong E, et al. 2012. J Immunol. 189:5667. PubMed
  43. White C, et al. 2015. J Immunol. 194:697. PubMed
  44. Matundan H, et al. 2019. J Virol. 93. PubMed
  45. Matundan HH, et al. 2021. J Virol. 95:e0103621. PubMed
  46. Wu G, et al. 2022. Wellcome Open Res. 6:134. PubMed
  47. Zheng D, et al. 2022. Acta Pharm Sin B. 12:2740. PubMed
  48. Vogel A, et al. 2022. STAR Protoc. 3:101653. PubMed
  49. Sun L, et al. 2015. Sci Rep. 5: 14871. PubMed
  50. Marshall N, et al. 2012. Cancer Res. 72:581. PubMed
  51. Yang C, et al. 2019. Nanomedicine (Lond). 14:2423. PubMed
  52. Tomay F, et al. 2019. J Transl Med. 17:237. PubMed
  53. Ma W, et al. 2017. Cell Death & Disease. 10.1038/cddis.2017.47. PubMed
  54. Zhang X, et al. 2022. JCI Insight. 7:. PubMed
  55. Fan Q, et al. 2021. Bioact Mater. 6:4014. PubMed
  56. Ye Y, et al. 2017. Sci Immunol. 2:17. PubMed
  57. Zhang W, et al. 2020. Nat Commun. 11:1187. PubMed
  58. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  59. Taddio MF, et al. 2021. Mol Imaging Biol. 23:196. PubMed
  60. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  61. Kelly SH, et al. 2021. ACS Biomater Sci Eng. 7:1876. PubMed
  62. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  63. Wang X, et al. 2021. EMBO J. 40:e105926. PubMed
  64. He J, et al. 2020. Evid Based Complement Alternat Med. 2020:5637507. PubMed
  65. Luck H, et al. 2019. Nat Commun. 10:3650. PubMed
  66. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  67. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  68. Izumi G, et al. 2021. Nat Commun. 12:5029. PubMed
  69. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  70. Li J, et al. 2020. Development. :. PubMed
  71. Simmons D, et al. 2012. J Immunol. 188:3116. PubMed
  72. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  73. Feng S, et al. 2021. Exp Ther Med. 21:20. PubMed
  74. Zhang Q, et al. 2022. Commun Biol. 5:544. PubMed
  75. Walker MT, et al. 2021. Front. Allergy. 2:. PubMed
  76. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  77. Tateishi R, et al. 2015. PLoS One. 10: e0141650. PubMed
  78. Kelly SH, et al. 2021. Adv Healthc Mater. 10:e2001614. PubMed
  79. Piñón-Zárate G, et al. 2022. Molecules. 27:. PubMed
  80. Vogel A, et al. 2022. Cell Rep. 38:110420. PubMed
  81. Yang Z, et al. 2021. Nat Commun. 12:4299. PubMed
  82. Miyauchi K, et al. 2021. Nat Commun. 12:3789. PubMed
  83. Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed
  84. Knox T, et al. 2019. Sci Rep. 9:6136. PubMed
  85. Kadir NA, et al. 2020. Pathogens. 9:00. PubMed
  86. Xiao Z, et al. 2022. Mater Today Bio. 15:100297. PubMed
  87. Zhang X, et al. 2021. Front Pharmacol. 12:706748. PubMed
  88. Koyama M et al. 2019. Immunity. 51(5):885-898 . PubMed
  89. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  90. Lightman SM, et al. 2020. Cell Reports. 1.086805556. PubMed
  91. Chen R, et al. 2021. Front Oncol. 11:743050. PubMed
  92. Wang Y, et al. 2020. Vaccines (Basel). 8:. PubMed
  93. Jeisy-Scott V, et al. 2012. J Virol. 86:10988. PubMed
  94. Liu WL, et al. 2019. Nat Commun. 10:3199. PubMed
  95. Kubli SP, et al. 2019. Nat Commun. 10:2678. PubMed
  96. Zhang Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  97. Lin YC, et al. 2020. Mol Med Rep. 22:4909. PubMed
RRID
AB_313128 (BioLegend Cat. No. 104707)
AB_313129 (BioLegend Cat. No. 104708)

Antigen Details

Structure
Ig superfamily, 60 kD
Distribution

Macrophages, activated B cells and T cells, dendritic cells

Function
T cell costimulation
Ligand/Receptor
CD28 (stimulatory), CD152(CTLA4) (inhibitory)
Cell Type
B cells, Dendritic cells, Macrophages, T cells, Tregs
Biology Area
Cell Biology, Costimulatory Molecules, Immunology, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Linsley PS, et al. 1991. J. Exp. Med. 174:561.
3. Salomon B, et al. 2001. Annu. Rev. Immunol. 19:225.

Gene ID
12519 View all products for this Gene ID
UniProt
View information about CD80 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 2    Revision Date: 02.18.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account